Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Cash & Equivalents (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Cash & Equivalents readings, the most recent being $12.9 million for Q4 2023.

  • On a quarterly basis, Cash & Equivalents rose 109.45% to $12.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $12.9 million, a 109.45% increase, with the full-year FY2023 number at $12.9 million, up 109.45% from a year prior.
  • Cash & Equivalents hit $12.9 million in Q4 2023 for Elicio Therapeutics, down from $14.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $130.5 million in Q1 2021 to a low of $598000.0 in Q2 2022.
  • Median Cash & Equivalents over the past 4 years was $21.7 million (2023), compared with a mean of $47.2 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 99.49% in 2022 and later surged 3525.75% in 2023.
  • Elicio Therapeutics' Cash & Equivalents stood at $34.6 million in 2020, then soared by 156.47% to $88.8 million in 2021, then crashed by 93.06% to $6.2 million in 2022, then surged by 109.45% to $12.9 million in 2023.
  • The last three reported values for Cash & Equivalents were $12.9 million (Q4 2023), $14.8 million (Q3 2023), and $21.7 million (Q2 2023) per Business Quant data.